A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension

Trial Profile

A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Diazoxide (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Sponsors Essentialis
  • Most Recent Events

    • 30 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 25 Sep 2015 Results published in an Essentialis media release.
    • 09 Sep 2015 According to an Essentialis media release, first patient has been dosed in the long-term extension study and data from are expected in Q1 of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top